Jump to content

Sinopharm (company)

Coordinates: 39°58′29″N 116°20′24″E / 39.9747°N 116.3401°E / 39.9747; 116.3401
From Wikipedia, the free encyclopedia
This article is about the pharmaceutical company. For the COVID-19 vaccine that it developed, see Sinopharm BIBP COVID-19 vaccine.
For other uses, see Sinopharm (disambiguation).
"Sinopharm" redirects here. Not to be confused with Sinovac Biotech.

39°58′29″N 116°20′24″E / 39.9747°N 116.3401°E / 39.9747; 116.3401

China National Pharmaceutical Group Corporation
Sinopharm
Company typeState-owned enterprise
Industry
FoundedNovember 26, 1998; 25 years ago (1998-11-26)
Headquarters20 Zhichun Road, Haidian District,
Beijing
,
China
Area served
China, exported worldwide
Key people
Liu Jingzhen (chairman & Chinese Communist Party Committee Secretary)[1][2]
Products
RevenueIncrease US$ 96.1 billion (2023)[3]
Increase US$ 1.1 billion (2023)[3]
Total assetsUS$ 82.8 billion (2023)[3]
OwnerChinese central government (100%)
Number of employees
202,426 (2023)[3]
Subsidiaries
Chinese name
Simplified Chinese中国医药集团总公司
Traditional Chinese中國醫藥集團總公司
Transcriptions
Standard Mandarin
Hanyu PinyinZhōngguó yīyào jítuán zǒng gōngsī
short Chinese name
Simplified Chinese国药集团
Traditional Chinese國藥集團
Transcriptions
Standard Mandarin
Hanyu PinyinGuóyào jítuán
Footnotes / references
in a consolidated basis; equity and profit excluded minority interests; in Chinese Accounting Standards[4]

China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group (SEHK: 1099, via a 51–49 joint venture, Sinopharm Industrial Investment, with Fosun Pharmaceutical), China Traditional Chinese Medicine [zh] (SEHK: 570, mostly via Sinopharm Group Hongkong Co., Ltd.),[5] Shanghai Shyndec Pharmaceutical (SSE: 600420, via a wholly owned research institute based in Shanghai), and Beijing Tiantan Biological Products (SSE: 600161, via China National Biotec Group).

China National Pharmaceutical Group was supervised by the State-owned Assets Supervision and Administration Commission of the State Council.[6]

Sinopharm was ranked 109th in the 2021 Fortune Global 500 list.[7]

History

[edit]

Sinopharm was founded as China National Pharmaceutical Group Corporation (Chinese: 中国医药集团总公司) on November 26, 1998, as a holding company for China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation (Chinese: 中国医药工业公司), China National Pharmaceutical Foreign Trade Corp. (Chinese: 中国医药对外贸易公司) and China National Medical Device (Chinese: 中国医疗器械工业公司). In 2009 it was merged with China National Biotec Group (Chinese: 中国生物技术集团公司).[citation needed]

Its subsidiary Wuhan Institute of Biological Products was fined for selling 400,520 ineffective DPT vaccines in November 2017.[8]

Pfizer announced the signing of a cooperation pact with Sinopharm Group in April 2023, with plans to seep approval for 12 drugs in China through 2025.[9]

COVID-19 vaccines

[edit]
Main articles: Sinopharm BIBP COVID-19 vaccine, Sinopharm WIBP COVID-19 vaccine, and Sinopharm CNBG COVID-19 vaccine

The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV,[10] the Sinopharm COVID-19 vaccine,[11] or BIBP vaccine,[11][12][13] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants.[14] BBIBP-CorV shares similar technology with CoronaVac and BBV152, other inactivated virus vaccines for COVID-19.[15]

Peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed BBIBP-CorV 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. 95 cases in placebo group).[16] In December 2020, the UAE previously announced interim results showing 86% efficacy.[17] While mRNA vaccines like the Pfizer–BioNTech COVID-19 vaccine and mRNA-1273 showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures.[18]

BBIBP-CorV is being used in vaccination campaigns by certain countries in Asia,[19][20][21] Africa,[22][23][24] South America,[25][26][27] and Europe.[28][29][30] Sinopharm expects to produce one billion doses of BBIBP-CorV in 2021.[31] On 7 May 2021, the World Health Organization approved the vaccine for emergency use[32] and Sinopharm later signed purchase agreements for 170 million doses from COVAX.[33]

The similarly named Sinopharm WIBP COVID-19 vaccine is also an inactivated virus vaccine.[citation needed]

See also

[edit]

References

[edit]
  1. ^ "中国医药集团有限公司主要领导调整" (in Chinese). Sinopharm. Archived from the original on 2022-09-08. Retrieved 2021-08-24.
  2. ^ "Liu Jingzhen". Bloomberg.
  3. ^ a b c d "Sinopharm". Fortune Global 500. Fortune. Retrieved 2024-08-24.
  4. ^ "中国医药集团总公司2016年度第一期超短期融资券发行披露材料" [Pospectus of 2016 (batch 1) Ultra-short-term financing of Sinopharm]. Sinopharm (in Chinese). Shanghai Clearing House. 19 January 2016. Retrieved 22 November 2016.
  5. ^ "2015 Annual Report" (PDF). China Traditional Chinese Medicine. Hong Kong Stock Exchange. 28 April 2016. Retrieved 22 November 2016.
  6. ^ "央企名录 (List of Central SOEs)". Official website of SASAC (in Chinese). Retrieved 3 March 2016.
  7. ^ "Global 500".
  8. ^ "Chinese President Xi Jinping orders crackdown over 'appalling' vaccine scandal". South China Morning Post. 23 July 2018. Retrieved 29 November 2018.
  9. ^ "Pfizer signs strategic cooperation pact with China's Sinopharm". Reuters. 2023-04-13. Retrieved 2023-11-08.
  10. ^ Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. (January 2021). "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial". The Lancet. Infectious Diseases. 21 (1): 39–51. doi:10.1016/s1473-3099(20)30831-8. PMC 7561304. PMID 33069281.
  11. ^ a b "The Sinopharm COVID-19 vaccine: What you need to know". World Health Organization. 10 May 2021. Retrieved 5 July 2021.
  12. ^ Nguyen S (5 June 2021). "Coronavirus: Vietnam approves Sinopharm's vaccine, but will people take it?". South China Morning Post. Retrieved 5 July 2021.
  13. ^ Lahiri T, Li J (16 June 2021). "What we now know about the efficacy of China's Covid-19 vaccines". Quartz. Retrieved 5 July 2021.
  14. ^ Liu, Roxanne; Munroe, Tony (2020-11-19). Sarkar, Himani (ed.). "China Sinopharm's coronavirus vaccine taken by about a million people in emergency use". Reuters. Beijing. Retrieved 2023-01-19.
  15. ^ Corum, Jonathan; Zimmer, Carl (2021-04-26). "How the Sinopharm Vaccine Works". The New York Times. ISSN 0362-4331. Retrieved 2021-04-29.
  16. ^ Kaabi, Nawal Al; Zhang, Yuntao; Xia, Shengli; et al. (May 26, 2021). "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial". JAMA. 326 (1): 35–45. doi:10.1001/jama.2021.8565. PMC 8156175. PMID 34037666.
  17. ^ "UAE: Ministry of Health announces 86 per cent vaccine efficacy". gulfnews.com. 9 December 2020. Retrieved 2020-12-13.
  18. ^ "China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says". Bloomberg.com. 2020-12-09. Retrieved 2020-12-09.
  19. ^ Liu R (2020-12-31). "China gives its first COVID-19 vaccine approval to Sinopharm". Reuters. Retrieved 2020-12-31.
  20. ^ Turak, Natasha (2021-01-18). "The UAE is on track to have half its population vaccinated by the end of March". CNBC. Retrieved 2021-01-21.
  21. ^ Dawn.com (2021-02-02). "PM Imran kicks off Pakistan's Covid-19 vaccination drive". DAWN.COM. Retrieved 2021-02-03.
  22. ^ Waly, Mohamed; Eltahir, Nafisa (2021-01-24). Richardson, Alex (ed.). "Sisi says Egypt to begin COVID-19 vaccinations on Sunday". Reuters. Cairo. Retrieved 2023-01-19.
  23. ^ Dumpis, Toms (2021-01-27). "Morocco Receives Half a Million Doses of Chinese Sinopharm Vaccine". Morocco World News. Retrieved 2021-01-28.
  24. ^ "Zimbabwe starts administering China's Sinopharm vaccines". thestar.com. 2021-02-18. Retrieved 2021-02-20.
  25. ^ "Argentina autoriza la vacuna china Sinopharm para mayores de 60 años". El Comercio. Retrieved 2021-03-26.
  26. ^ Aquino, Marco (2021-02-10). "'The best shield': Peru launches inoculation drive with Sinopharm vaccine". Reuters. Retrieved 2021-02-10.
  27. ^ "Bolivia begins inoculation with Sinopharm jabs | The Star". www.thestar.com.my. Retrieved 2021-02-28.
  28. ^ "Serbia Becomes First European Nation To Use China's Sinopharm Vaccine". Radio Free Europe/Radio Liberty. 20 January 2021. Retrieved 2021-01-21.
  29. ^ "Hungary first EU nation to use China's Sinopharm vaccine against COVID". euronews. 2021-02-24. Retrieved 2021-02-26.
  30. ^ "Belarus begins COVID-19 vaccinations with Chinese shots". eng.belta.by. 2021-03-15. Retrieved 2021-03-16.
  31. ^ "Which companies will likely produce the most COVID-19 vaccine in 2021?". Pharmaceutical Processing World. 2021-02-05. Retrieved 2021-02-28.
  32. ^ Taylor, Adam (7 May 2021). "WHO grants emergency use authorization for Chinese-made Sinopharm coronavirus vaccine". The Washington Post. Retrieved 7 May 2021.
  33. ^ "Chinese drugmakers agree to supply more than half a billion vaccines to COVAX". Reuters. 2021-07-12. Retrieved 2021-07-13.
[edit]
Retrieved from "https://wiki.riteme.site/w/index.php?title=Sinopharm_(company)&oldid=1252297487"